Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ICPT's Cash to Debt is ranked higher than
88% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. ICPT: No Debt )
ICPT' s 10-Year Cash to Debt Range
Min: 215.94   Max: No Debt
Current: No Debt

Equity to Asset 0.93
ICPT's Equity to Asset is ranked higher than
97% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. ICPT: 0.93 )
ICPT' s 10-Year Equity to Asset Range
Min: -1.08   Max: 0.93
Current: 0.93

-1.08
0.93
Interest Coverage No Debt
ICPT's Interest Coverage is ranked higher than
93% of the 454 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.71 vs. ICPT: No Debt )
ICPT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 174.04
M-Score: -2.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2432.31
ICPT's Operating margin (%) is ranked lower than
58% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. ICPT: -2432.31 )
ICPT' s 10-Year Operating margin (%) Range
Min: -2432.31   Max: -766.2
Current: -2432.31

-2432.31
-766.2
Net-margin (%) -4179.53
ICPT's Net-margin (%) is ranked lower than
58% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. ICPT: -4179.53 )
ICPT' s 10-Year Net-margin (%) Range
Min: -4179.53   Max: -705.71
Current: -4179.53

-4179.53
-705.71
ROE (%) -82.27
ICPT's ROE (%) is ranked lower than
54% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. ICPT: -82.27 )
ICPT' s 10-Year ROE (%) Range
Min: -82.27   Max: -66.21
Current: -82.27

-82.27
-66.21
ROA (%) -45.10
ICPT's ROA (%) is ranked lower than
53% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. ICPT: -45.10 )
ICPT' s 10-Year ROA (%) Range
Min: -65.42   Max: -38.9
Current: -45.1

-65.42
-38.9
ROC (Joel Greenblatt) (%) -2359.57
ICPT's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. ICPT: -2359.57 )
ICPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12693.96   Max: -2359.57
Current: -2359.57

-12693.96
-2359.57
» ICPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ICPT Guru Trades in Q3 2013

Steven Cohen 601,100 sh (+380.88%)
» More
Q4 2013

ICPT Guru Trades in Q4 2013

Steven Cohen 1,249,046 sh (+107.79%)
» More
Q1 2014

ICPT Guru Trades in Q1 2014

Jim Simons 6,500 sh (New)
RS Investment Management 39,261 sh (New)
Columbia Wanger 133,000 sh (New)
Andreas Halvorsen 454,917 sh (New)
Steven Cohen 5,171 sh (-99.59%)
» More
Q2 2014

ICPT Guru Trades in Q2 2014

Chuck Royce 360 sh (New)
Columbia Wanger 183,300 sh (+37.82%)
Steven Cohen 26,500 sh (unchged)
Jim Simons Sold Out
Andreas Halvorsen 208,077 sh (-54.26%)
RS Investment Management 3,214 sh (-91.81%)
» More
» Details

Insider Trades

Latest Guru Trades with ICPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Intercept Pharmaceuticals Inc

Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc., Micron Technology Inc., Facebook Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Intercept Pharmaceuticals Inc., Micron Technology Inc. and Facebook Inc. Read more...

Ratios

vs
industry
vs
history
P/B 21.16
ICPT's P/B is ranked lower than
65% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. ICPT: 21.16 )
ICPT' s 10-Year P/B Range
Min: 5.32   Max: 104.9
Current: 21.16

5.32
104.9
P/S 3621.50
ICPT's P/S is ranked lower than
70% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. ICPT: 3621.50 )
ICPT' s 10-Year P/S Range
Min: 43.77   Max: 5778.25
Current: 3621.5

43.77
5778.25
EV-to-EBIT -75.97
ICPT's EV-to-EBIT is ranked higher than
56% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. ICPT: -75.97 )
ICPT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -75.97

Current Ratio 25.72
ICPT's Current Ratio is ranked higher than
99% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. ICPT: 25.72 )
ICPT' s 10-Year Current Ratio Range
Min: 0.48   Max: 25.72
Current: 25.72

0.48
25.72
Quick Ratio 25.72
ICPT's Quick Ratio is ranked higher than
99% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. ICPT: 25.72 )
ICPT' s 10-Year Quick Ratio Range
Min: 0.48   Max: 25.72
Current: 25.72

0.48
25.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.04
ICPT's Price/Net Cash is ranked higher than
90% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ICPT: 22.04 )
ICPT' s 10-Year Price/Net Cash Range
Min: 7.47   Max: 18.45
Current: 22.04

7.47
18.45
Price/Net Current Asset Value 22.04
ICPT's Price/Net Current Asset Value is ranked higher than
85% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ICPT: 22.04 )
ICPT' s 10-Year Price/Net Current Asset Value Range
Min: 7.42   Max: 18.45
Current: 22.04

7.42
18.45
Price/Tangible Book 21.16
ICPT's Price/Tangible Book is ranked higher than
55% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. ICPT: 21.16 )
ICPT' s 10-Year Price/Tangible Book Range
Min: 7.34   Max: 17.71
Current: 21.16

7.34
17.71
Price/Median PS Value 6.11
ICPT's Price/Median PS Value is ranked higher than
51% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. ICPT: 6.11 )
ICPT' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 6.95
Current: 6.11

0.09
6.95

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:I4P.Germany
Intercept Pharmaceuticals Inc was incorporated in the State of Delaware on September 4, 2002. It is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry. The Company's product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. The Company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which it believes has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial that it anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. The Company currently expects results from the trial to be available by mid-2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC. The Company owns worldwide rights to OCA outside of Japan and China, where it has exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. The Company is currently conducting an open label Phase 2a trial of OCA in patients with portal hypertension, and it anticipate receiving results from the 10 mg dose group of this trial by the end of 2012. The key elements of its strategy are to: complete the development of OCA for its lead indication, PBC; obtain regulatory approval of OCA for the treatment of PBC in the United States, Europe and other countries; commercialize OCA in the United States, Europe and other countries, initially for the treatment of PBC; continue to develop OCA in other orphan and more prevalent liver and other diseases; and advance the earlier stage product candidates in its pipeline. Some of the competitors are Eli Lilly, Exelixis, Inc. and Phenex Pharmaceuticals AG. Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those it is developing.
» More Articles for ICPT

Headlines

Articles On GuruFocus.com
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc., Micron Technology Inc., Facebook Inc. Apr 14 2014 
President and CEO of Intercept Pharmaceuticals Inc. Mark Pruzanski Sold 37,500 Shares Jul 11 2013 
Weeky CFO Sells Highlight: ADBE, HAE, WAGE, OVTI, ICPT Jun 24 2013 

More From Our Partners
3 Biotechs Surging Following InterMune Takeover - Analyst Blog Aug 26 2014 - ZACKS

More From Other Websites
4 Biotechs That Might Be Bought Soon Aug 29 2014
[video] 3 Russell outperformers Aug 28 2014
Insider Trading Alert - ACHC, ARO And ICPT Traded By Insiders Aug 28 2014
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology... Aug 27 2014
3 Biotechs Surging Following InterMune Takeover Aug 26 2014
Intercept to Present at Upcoming Investor Conferences Aug 26 2014
[video] $8.3 billion biotech deal Aug 25 2014
Biotech Bounce Gets More Fuel From InterMune Deal Aug 25 2014
InterMune Stock Spikes On Rare Big Biotech Buyout Aug 25 2014
INTERCEPT PHARMACEUTICALS INC Financials Aug 19 2014
Intercept Pharmaceuticals: Curb Your Enthusiasm? Aug 15 2014
[video] MannKind Snares Sanofi, Intercept Soars & Southwest's Mexico Move Aug 15 2014
Coverage initiated on Intercept Pharma by FBR Capital Aug 15 2014
Roses in the Market Aug 13 2014
Intercept Pharmaceuticals Posts Earnings, Pipeline in Focus Aug 13 2014
Intercept Pharmaceuticals (ICPT) Worth Watching: Stock Gains 16.6% Aug 13 2014
[video] Stock Pops & Drops: ICPT, TSL, NUAN, RAX Aug 12 2014
Roses in the Market... Aug 12 2014
[video] Stocks Close Down on Light Volume, Pump Prices Expected to Fall Aug 12 2014
U.S. stocks end lower; Dow turns negative for the year Aug 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK